Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the EBITDA margin high or low?
The EBITDA margin of -52.21% is 48% above its 5-year average of -100.07%, near the high end of its 5-year range (-168.10%–-45.06%).
0.95% above its 12-month average of -52.71%.
Reported quarterly EBITDA margin; no daily interpolation. Q2 FY2026 (2026-06-30): -45.06%.
EBITDA MARGIN
-52.21%
EBITDA MARGIN AVG TTM
-52.71%
EBITDA MARGIN AVG 3Y
-82.26%
EBITDA MARGIN AVG 5Y
-100.07%
EBITDA MARGIN AVG 10Y
N/A
EBITDA MARGIN AVG 15Y
N/A
EBITDA MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
+0.95%
CURRENT VS 3Y AVG
+36.53%
CURRENT VS 5Y AVG
+47.83%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
Outset Medical, Inc.
Market Cap
$76.74M
EBITDA Margin
-52.21%
TTM Avg
-52.71%
3Y Avg
-82.26%
5Y Avg
-100.07%
Market Cap
$77.54M
EBITDA Margin
-145368.18%
TTM Avg
-145368.18%
3Y Avg
-145368.18%
5Y Avg
-145368.18%
Market Cap
$75.95M
EBITDA Margin
1.51%
TTM Avg
-4.98%
3Y Avg
-8.74%
5Y Avg
-7.62%
Market Cap
$78.07M
EBITDA Margin
-128297.25%
TTM Avg
-89238.38%
3Y Avg
-49477.43%
5Y Avg
-36037.89%
Market Cap
$78.29M
EBITDA Margin
-43906.17%
TTM Avg
-45201.13%
3Y Avg
-29968.45%
5Y Avg
-38423.13%
Market Cap
$75.18M
EBITDA Margin
-58.13%
TTM Avg
-62.55%
3Y Avg
-79.72%
5Y Avg
-85.39%
Market Cap
$78.59M
EBITDA Margin
-2368.83%
TTM Avg
-2368.83%
3Y Avg
-1339.96%
5Y Avg
-991.53%
Market Cap
$79.61M
EBITDA Margin
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | EBITDA MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Outset Medical, Inc. (OM) | $76.74M | -52.21% | -52.71% | -82.26% | -100.07% |
| Neonc Technologies Holdings, Inc. (NTHI)vs › | $77.54M | -145368.18% | -145368.18% | -145368.18% | -145368.18% |
| SkinHealth Systems Inc. (SKIN)vs › | $75.95M | 1.51% | -4.98% | -8.74% | -7.62% |
| Inovio Pharmaceuticals, Inc. (INO)vs › | $78.07M | -128297.25% | -89238.38% | -49477.43% | -36037.89% |
| Sera Prognostics, Inc. (SERA)vs › | $78.29M | -43906.17% | -45201.13% | -29968.45% | -38423.13% |
| Pulmonx Corporation (LUNG)vs › | $75.18M | -58.13% | -62.55% | -79.72% | -85.39% |
| vTv Therapeutics Inc. (VTVT)vs › | $78.59M | -2368.83% | -2368.83% | -1339.96% | -991.53% |
| Citius Oncology, Inc. (CTOR)vs › | $79.03M | N/A | N/A | N/A | N/A |
| Acrivon Therapeutics, Inc. Common Stock (ACRV)vs › | $79.61M | N/A | N/A | N/A | N/A |
| Hyperfine, Inc. (HYPR)vs › | $73.27M | -257.20% | -292.35% | -520.13% | -2376.66% |
Gross Margin
41.8%
EBITDA Margin
-52.2%
Operating Margin
-56.1%
Net Margin
-63.1%
Formula: EBITDA Margin = (EBITDA / Revenue) × 100
Why EBITDA Margin matters:
EBITDA Margin = EBITDA / Revenue
EBITDA margin measures operating profitability before interest, taxes, depreciation, and amortization as a percentage of revenue.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EBITDA MARGIN |
|---|---|
| 2026-06-30 | -45.06% |
| 2026-03-31 | -57.87% |
| 2025-12-31 | -58.00% |
| 2025-09-30 | -52.63% |
| 2025-06-30 | -50.00% |
| 2025-03-31 | -50.77% |
| 2024-12-31 | -69.41% |
| 2024-09-30 | -75.66% |
| 2024-06-30 | -106.96% |
| 2024-03-31 | -125.86% |
| 2023-12-31 | -117.70% |
| 2023-09-30 | -143.84% |
| 2023-06-30 | -115.58% |
| 2023-03-31 | -124.92% |
| 2022-12-31 | -119.56% |
| 2022-09-30 | -141.94% |
| 2022-06-30 | -168.10% |
| 2022-03-31 | -115.26% |
| 2021-12-31 | -139.39% |
| 2021-09-30 | -109.53% |
| 2021-06-30 | -113.42% |
| 2021-03-31 | -124.06% |
| 2020-12-31 | -172.12% |
| 2020-09-30 | -292.96% |
| 2020-06-30 | -207.95% |
| 2020-03-31 | -276.84% |
| 2019-12-31 | -250.49% |
| 2019-09-30 | -696.58% |
| 2019-06-30 | -570.09% |
| 2019-03-31 | -648.66% |
